References in periodicals archive ?
We believe that Probiodrug s CDK9 inhibitor program, while early stage, shows potential and we look forward to continuing its development.
In multiple myeloma, the addition of ERK5 inhibition and the established roles of the JAK-STAT and CDK9 pathways in myeloma cell survival and drug resistance suggest that TG02 could be an exciting addition to the armamentarium for this disease.
This activity was consistent with modulation of CDK7 and CDK9 inhibition and supports investigation of SNS-032 in B-cell malignancies such as chronic lymphocytic leukemia and multiple myeloma.
Seliciclib is an orally available cyclin dependent kinase (CDK) inhibitor that selectively inhibits multiple enzyme targets, CDK2/E, CDK2/A, CDK7 and CDK9, that are central to the process of cell division and cell cycle control.
In addition, peripheral blood cells obtained from patients treated with SNS-032 in a Phase 1 solid tumor clinical trial showed CDK7 and CDK9 inhibition, as well as down-modulation of the survival signaling protein Mcl-1.
Acronyms browser ?
Full browser ?
- CDK2-associated dual specificity phosphatase
- CDK2-associated dual-specificity phosphatase
- CDK4 gene
- CDK4 gene
- CDK4 inhibitor p16-INK4, INK4a
- CDK4B inhibitor
- CDK5-Binding Protein
- CDK6 inhibitor p18
- CDK8 protein kinase
- CDK8-like cyclin-dependent kinase
- CDK9-associated C-type protein